Epidemiologic, immunologic and practical considerations in developing and evaluating a human hookworm vaccine

Expert Review of Vaccines

Volumn 4, Issue 1, 2005, Pages 35-50

  Brooker, Simon ^b,c   Bethony, Jeffrey M ^a,b,d   Rodrigues, Laura C ^b,c   Alexander, Neal ^b,c   Geiger, Stefan M ^a,b,d,e   Hotez, Peter J ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Human Hookworm Vaccine Initiative   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hookworm; Recombinant vaccine

Indexed keywords

ALBENDAZOLE; ALUMINUM HYDROXIDE; ANTHELMINTIC AGENT; BENZIMIDAZOLE DERIVATIVE; COMPLEMENTARY DNA; HOOKWORM VACCINE; MEBENDAZOLE; PRAZIQUANTEL; RECOMBINANT ANTIGEN; RECOMBINANT ASP2 ANTIGEN; TIABENDAZOLE; UNCLASSIFIED DRUG;

ANCYLOSTOMA DUODENALE; ANEMIA; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; EPIDEMIOLOGICAL DATA; EVALUATION; HOOKWORM INFECTION; HUMAN; IMMUNOPHARMACOLOGY; INFECTION CONTROL; INFECTION RATE; METHODOLOGY; MOLECULAR BIOLOGY; NECATOR AMERICANUS; NONHUMAN; PARASITOSIS; PREVALENCE; PRIORITY JOURNAL; REINFECTION; REVIEW; SCHOOL; STATISTICAL ANALYSIS;

EID: 14744280289     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.1.35     Document Type: Review

References (101)

1. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 363, 150-156 (2004).
2. Brodskyn C, de Oliveira CI, Barral A, Barral-Netto M. Vaccines in leishmaniasis: advances in the last 5 years. Expert Rev. Vaccines 2, 705-717 (2003).
3. Capron A, Riveau GJ, Bartley PB, McManus DP. Prospects for a schistosome vaccine. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2, 281-290 (2002).
4. Hotez PJ, Zhan B, Bethony JM et al. Progress in the development of a recombinant vaccine for human hookworm disease: the human hookworm vaccine initiative. Int. J. Parasitol. 33, 1245-1258 (2003).
5. de Silva NR, Brooker S, Hotez PJ et al. Soil-transmitted helminth infections: updating the global picture. Trends Parasitol. 19, 547-551 (2003).
6. Hotez PJ, Brooker S, Bethony JM et al. Hookworm infection. N. Engl. J. Med. 351, 799-807 (2004).
7. WHO. Annex Table 3, Burden of disease in DALYs by cause, sex and mortality stratum in WHO Regions, estimates for 2001. In: The World Health Report 2002, Reducing Risks, Promoting Health Life. World Health Organization, Geneva, 192-193 (2002).
8. WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiases. WHO Technical Report Series 912. World Health Organization, Geneva, 2 (2002).
9. Hoagland KE, Schad GA. Necator americanus and Ancylostoma duodenale: life history parameters and epidemiological implications of two sympatric hookworms of humans. Exp. Parasitol. 44, 36-49 (1978).
10. Crompton DWT, Stephenson LS. Hookworm infection, nutritional status and productivity. In: Hookworm Disease Current Status and New Directions. Schad GA, Warren KS (Eds). Taylor and Francis, London, UK, 231-264 (1990).
11. Stoltzfus RJ, Chwaya HM, Tielsch JM et al. Epidemiology of iron-deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Am. J. Clin. Nutr. 65, 153-159 (1997).
12. Horton RJ. Benzimidoles in a wormy world. Parasitol. Today 6, 106 (1990).
13. Lacey E. Mode of action of Benzimidazoles. Parasitol. Today 6, 112-115 (1990).
14. Utzinger J, Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin. Pharmaco. 5, 263-286 (2004). Reviews the development, current experience and future prospects of human anthelmintic chemotherapy.
15. Bennett A, Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol. Today 16, 71-74 (2000). Analyzes published data on cure rates and egg reduction rates of mebendazole and albendazole for treating intestinal nematode infections in humans.
16. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 121, S113-S132 (2000). Summarizes the efficacy and safety of albendazole's use as an anthelminthic in humans.
17. Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a review. Trop. Med. Int. Health 6, 915-921 (2001). Critically analyzes reports on drug resistance in human helminths and reviews experiences with helminths of livestock.
18. de Silva NR. Impact of chemotherapy on the morbidity due to soil-transmitted nematodes. Acta Trop. 96, 197-214 (2003).
19. Brooker S, Bethony J, Hotez PJ. Human hookworm infection in the 21st century. Adv. Parasitol. 58, 197-288 (2004).
20. Partnership for Child Development. Better health, nutrition and education for the school-aged child. Trans. R. Soc. Trop. Med. Hyg. 91, 1-2 (1997).
21. Savioli L, Stansfield S, Bundy DAP et al. Schistosomiasis and soil-transmitted helminth infections: forging control efforts. Trans. R. Soc. Trop. Med. Hyg. 96, 577-579 (2002).
22. Albonico M, Smith PG, Ercole E et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Trans. R. Soc. Trop. Med. Hyg. 89, 538-541 (1995).
23. Quinnell RJ, Slater AFG, Tighe P et al. Reinfection with hookworm after chemotherapy in Papua New Guinea. Parasitology 106, 379-385 (1993).
24. Anderson RM, Medley GF. Community control of helminth infections of man by mass and selective chemotherapy. Parasitology 90, 629-660 (1985).
25. Chan MS, Bradley M, Bundy DAP. Transmission patterns and the epidemiology of hookworm. Int. J. Epidemiol. 26, 1392-1400 (1997). Describes models of hookworm transmission dynamics where school-based, adult- and population-targeted chemotherapy programs are compared.
26. Tanner M, Evans D. Vaccines or drugs: complementarity is crucial. Parasitol. Today 10, 196-202 (1994).
27. Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev. 13, 207-222 (2000).
28. de Clerq D, Sacko M, Behnke J et al. Failure of mebendazole in treatment of human hookworm infection in the southern region of Mali. Am. J. Trop. Med. Hyg. 57, 25-30 (1997).
29. Reynoldson JA, Behnke JM, Pallant LJ et al. Failure of pyrantel in treatment of human hookworm infection (Ancylostoma duodenale) in the Kimberely region of North West Australia. Acta Tropica 68, 301-312 (1997).
30. Albonico M, Bickle Q, Ramsan M et al. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull. WHO 81, 343-352 (2003). Provide field data on the reduced efficacy of anthelminthic following repeated rounds of treatment.
31. Horton J. Global anthelmintic chemotherapy programs: learning from history. Trends Parasitol. 19, 405-409 (2003).
32. Bundy DAP, Chan MS, Guyatt HL. The practicality and sustainability of vaccination as an approach to parasite control. Parasitology 110, S51-S58 (1995). Reviews the understanding of parasite population dynamics and epidemiology and how these influence the feasibility and sustainability of any new vaccine.
33. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, UK (1991).
34. Anderson RM. The population dynamics and control of hookworm and roundworm infection. In: Population Dynamics of Infectious Diseases: Theory and Applications. Anderson RM (Ed.). Chapman and Hall, London, UK, 67-109 (1982).
35. Bundy DAP, Medley GE Immunoepidemiology of human geohelminthiasis: ecological and immunological determinants of worm burden. Parasitology 104, S105-S119 (1992).
36. Shapiro AE, Tukahebwa EM, Kasten J et al. Epidemiology of helminth infections and their relationship to clinical malaria in southwest Uganda. Trans. R. Soc. Trop. Med. Hyg. 99, 18-24 (2005).
37. Basch PF. Antischistosomal vaccines: beyond the laboratory. Trans. Roy. Soc. Trop. Med. Hyg. 87, 589-592 (1993).
38. Fine PEM. Herd immunity: history, theory, practice. Epidemiol Rev. 15(2), 265-302 (1993).
39. Loukas A, Prociv P. Immune responses in hookworm infections. Clin. Microbiol. Rev. 14, 689-703 (2001). Thorough review of hookworm biology, immune responses against the different parasitic stages and parasite mechanisms to escape the host's immune response.
40. Carr A, Pritchard DI. Antigen expression during development of the human hookworm, Necator americanus (Nematoda). Parasite Immunol. 9, 219-234 (1987).
41. Pritchard DI, Walsh EA, Quinnell RJ et al. Isotypic variation in antibody responses in a community in Papua New Guinea to larval and adult antigens during infection, and following reinfection, with the hookworm Necator americanus. Parasite Immunol. 6, 617-631 (1992).
42. Fulford AJC, Webster M, Ouma JH, Kimani G, Dunne DW. Puberty and age-related changes in susceptibility to schistosome infection. Parasitol. Today 14, 23-26 (1998).
43. Dessein AJ, Marquet S, Henri S et al. Infection and disease in human Schistosomiasis mansoni are under distinct major gene control. Microbes Infect. 1, 561-567 (1999).
44. Corrêa-Oliveira R, Golgher DB, Oliveira GC et al. Infection with Schistosoma mansoni correlates with altered immune responses to Ascaris lumbricoides and hookworm. Acta Trop. 83, 123-132 (2002).
45. Jarrett E, Bazin H. Elevation of total serum IgE in rats following helminth parasite infection. Nature 251 (5476), 613-614 (1974).
46. Pritchard DI, Quinnell RJ, Walsh EA. Immunity in humans to Necator americanus: IgE, parasite weight and fecundity. Parasite Immunol. 2, 71-75 (1995).
47. Pritchard DI. Atopy and helminth parasites. Int. J. Parasitol. 2, 167-168 (1993).
48. Pritchard DI, Brown A. Is Necator americanus approaching a mutualistic symbiotic relationship with humans? Trends Parasitol. 4, 169-172 (2001)
49. Boag PR, Parsons JC, Presidente PJ, Spithill TW, Sexton JL. Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum. Vet. Immunol. Immunopathol. 92(1-2), 87-94 (2003).
50. Geiger SM, Massara CL, Bethony J, Soboslay PT, Correa-Oliveira R. Cellular responses and cytokine production in post-treatment hookworm patients from an endemic area in Brazil. Clin. Exp. Immunol. 2, 334-340 (2004).
51. Quinnell RJ, Pritchard DI, Raiko A, Brown AP, Shaw MA. Immune responses in human necatoriasis: association between interleukin-5 responses and resistance to reinfection. J. Infect. Dis. 190(3), 430-438 (2004). One of the first articles evaluating the cellular immune response against hookworm infection and during reinfection. Associates interleukin-5 secretion in peripheral blood mononuclear cells with resistance to reinfection.
52. Maizels RM, Balic A, Gomez-Escobar N et al. Helminth parasites - masters of regulation. Immunol. Rev. 201, 89-116 (2004). State-of-the-art review regarding the knowledge in immunoregulation due to helminth parasites. Integrates experimental models with human studies and attempts to shed some light on the complex cytokine network and the parasite-host interactions.
53. Hesse M, Piccirillo CA, Belkaid Y et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J. Immunol. 5, 3157-3166 (2004).
54. Ghosh K, Hotez PJ. Antibody-dependent reductions in mouse hookworm burden after vaccination with Ancylostoma caninum secreted protein 1. J. Infect. Dis. 5, 1674-1681 (1999).
55. Girod N, Brown A, Pritchard DI, Billett EE. Successful vaccination of BALB/c mice against human hookworm (Necator americanus): the immunological phenotype of the protective response. Int. J. Parasitol. 1, 71-80 (2003).
56. Wilson AR, Coulson PS. Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes Infect. 1, 535-543 (1999).
57. Elias D, Wolday D, Akuffo H et al. Effect of deworming on human T-cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacillus Calmette-Guerin (BCG) vaccination. Clin. Exp. Immunol. 123, 219-225 (2001).
58. Chow SC, Brown A, Pritchard D. The human hookworm pathogen Necator americanus induces apoptosis in T-lymphocytes. Parasite Immunol. 1, 21-29 (2000). Important article for the discovery of molecules and mechanisms through which hookworms may evade the host's immune system. Demonstrates that the parasites can disarm host effector mechanisms or redirect the immune response in order to create a site of immune privilege.
59. Culley FJ, Brown A, Conroy DM et al. Eotaxin is specifically cleaved by hookworm metalloproteases preventing its action in vitro and in vivo. J. Immunol. 11, 6447-6453 (2000). Important article for the discovery of molecules and mechanisms through which hookworms may evade the host's immune system. Demonstrates that the parasites can disarm host effector mechanisms or redirect the immune response in order to create a site of immune privilege.
60. Hsieh GC, Loukas A, Wahl AM et al. A secreted protein from the human hookworm Necator americanus binds selectively to NK cells and induces IFN-γ production. J. Immunol. 173(4), 2699-2704 (2004). Important article for the discovery of molecules and mechanisms through which hookworms may evade the host's immune system. Demonstrates that the parasites can disarm host effector mechanisms or redirect the immune response in order to create a site of immune privilege.
61. Hawdon JM, Hotez PJ. Hookworm: developmental biology of the infectious process. Curr. Opin. Genet. Dev. 6, 618-623 (1996).
62. Loukas A, Constant SL, Bethony JM. Immunobiology of hookworm infection. FEMS Microrev. (2005).
63. Maizels RM, Holland MJ, Falcone FH, Zang XX, Yazdanbakhsh M. Vaccination against helminth parasites - the ultimate challenge for vaccinologists? Immunol. Rev. 171, 125-147 (1999).
64. Bungito RD, Green J, Kruglov E, Cappello M. Mitigation of hookworm disease by immunization with soluble extracts of Ancylostoma ceylanicum. J. Infect. Dis. 183, 1380-1387 (2001).
65. Allen JE, MacDonald AS. Profound suppression of cellular proliferation mediated by the secretions of nematodes. Parasite Immunol. 20, 241-247 (1998).
66. Miller TA. Industrial development and field use of the canine hookworm vaccine. Adv. Parasitol. 16, 333-342 (1978).
67. Hotez PJ, Ghosh K, Hawdon JM et al. Experimental approaches to the development of a recombinant hookworm vaccine. Immunol. Rev. 171, 163-171 (1999).
68. Hawdon JM, Narasmihan S, Hotez PJ. Ancylostoma secreted protein 2: cloning and characterization of a second member of a family of nematode-secreted proteins from Ancylostoma caninum. Mol. Biochem. Parasitol. 30, 149-165 (1999).
69. Goud GN, Zhan B, Ghosh K et al. Cloning, yeast expression, isolation and vaccine testing of recombinant Ancylostoma-secreted protein 1 (ASP-1) and ASP-2 from Ancylostoma ceylanicum. J. Infect. Dis. 189, 919-929 (2004).
70. Mendez S, Zhan B, Goud G et al. Effect of combining the larval antigens Ancylostoma-secreted protein 2 (ASP-2) and metalloprotease 1 (MTP-1) in protecting hamsters against hookworm infection and disease caused by Ancylostoma ceylanicum. Vaccine (2005) (In Press).
71. Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Buss P. Hookworm - the great infection of mankind. PLoS Medicine (2005) (In Press).
72. Zhan B, Wang Y, Liu YY et al. Ac-SAA-1 an immunodominant 16-kDa surface-associated antigen of infective larvae and adults of Ancylostoma caninum. Int. J. Parasitol. 34, 1037-1045 (2004).
73. Zhan B, Hotez PJ, Wang Y, Hawdon J. A developmentally regulated metalloprotease secreted by host stimulated Ancylostoma caninum third-stage infective larvae is a member of the astacin family of proteases. Mol. Bio. Parasitol. 120, 291-296 (2002).
74. Williamson AL, Lecchi P, Turk BE et al. A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J. Bio. Chem. 279, 35950-35957 (2004).
75. Williamson AL, Brindley PJ, Knox, DP, Hotez PJ, Loukas A. Digestive proteases of blood-feeding nematodes and other parasites. Trends Parasitol. 19, 417-423 (2003).
76. Loukas A, Bethony JM, Williamson AL et al. Vaccination of dogs with recombinant cysteine protease from the intestine of canine hookworms diminishes fecundity and growth of worms. J. Infect. Dis. 189, 1952-1961 (2004).
77. Williamson AL, Lecchi P, Turk BE et al. A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J. Biol. Chem. 279, 35950-35957 (2004).
78. Jones BF, Hotez PJ. Molecular cloning and characterization of Ac-mep-1, a developmentally regulated gut luminal metalloendopeptidase from adult Ancylostoma caninum hookworms. Mol. Biochem. Parasitol. 119, 107-116 (2002).
79. Orenstein WA, Bernier RH, Hinman AJ. Assessing vaccine efficiency in the field. Epidemiol. Rev. 10, 212-241 (1988).
80. Smith PG. Evaluating interventions against tropical diseases. Int. J. Epidemiol. 16, 159-166 (1987).
81. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 275, 390-397 (1996).
82. Jaffar S, Leach A, Hall AJ et al. Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation? Vaccine 18, 633-640 (2000).
83. Hayes RJ, Alexander ND, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stats. Methods Med. Res. 9(2), 95-116 (2000).
84. Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against Schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 66, 348-358 (2002). Discusses desired characteristics of a schistosomal vaccine and the practical steps required to develop such a vaccine.
85. Booth M, Vounatsou P, N'goran EK, Tanner M, Utzinger J. The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm coinfections in rural Cote d'Ivoire. Parasitology 127, 525-531 (2003).
86. Stoltzfus RJ, Albonico M, Chwaya HM et al. Hemoquant determination of hookworm-related blood loss and its role in iron deficiency in African children. Am. J. Trop. Med. Hyg. 55(4), 399-404 (1996). Provides data on the relationships among hookworm infection, intestinal blood loss, and iron status among school children.
87. Bradley M, Chandiwana SK, Bundy DAP, Medley GF. The epidemiology and population biology of Necator americanus infection in a rural community in Zimbabwe. Trans. R. Soc. Trop. Med Hyg. 86, 73-76 (1992). causes of hookworm anemia. Am. J. Trop. Med. Hyg. 15, 1031-110 (1966).
88. Bradley M, Chandiwana SK, Bundy DAP, Medley GF. The epidemiology and population biology of Necator americanus infection in a rural community in Zimbabwe. Trans. R. Soc. Trop. Med Hyg. 86, 73-76 (1992). causes of hookworm anemia. Am. J. Trop. Med. Hyg. 15, 1031-110 (1966).
89. Guyatt HL. The economics of worm control. In: The Geohelminths. Ascaris, Trichuris and Hookworm. Holland CV, Kennedy MW (Eds). Kluwer Academic Publishers, Boston, USA, 75-87 (2001). Summarizes and evaluates the costs incurred in implementing school-based delivery of anthelmintics.
90. Beutels P, van Doorslaer E, van Damme, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev. Vaccines 2, 89-100 (2003).
91. Guyatt HL, Evans D. Desirable characteristics of a schistosomiasis vaccine: some implications of a cost-effectiveness analysis. Acta Tropica 59, 197-209 (1995). Investigates the relative cost effectiveness of a vaccine for schistosomiasis relative to chemotherapy.
92. Chan MS, Woolhouse MEJ, Bundy DAP. Human schistosomiasis: potential long term consequences of vaccination programs. Vaccine 15, 1545-1550 (1997).
93. Graves PM. Comparison of the cost effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria. Ann. Trop. Med. Parasitol. 92, 399-410 (1998).
94. Gryseels B. Schistosomiasis vaccines: a devil's advocate view. Parasitol. Today 16, 46-48 (2000). Adopting a position of devil's advocate, raises some scientific, ethical and practical concerns about develop a schistosomal vaccine.
95. Boily MC, Masse BR, Desai K, Alary M, Anderson RM. Some important issues in the planning of Phase III HIV vaccine efficacy trials. Vaccine 17, 989-1004 (1999).
96. Williams GM, Sleigh AC, Li Y et al. Mathematical modeling of Schistosomiasis japonica: comparison of control strategies in the People's Republic of China. Acta Trop. 82, 253-262 (2002).
97. Chan MS, Guyatt HL, Bundy DAP, Medley GF. The development and validation of an age-stratified model for the evaluation of disease control strategies for intestinal helminths. Parasitology 109, 389-396 (1994).
98. McCullagh P, Nelder JA. Generalized Linear Models. Chapman and Hall/CRC, London, UK (1989).
99. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. 4th Edition. Blackwell Scientific Publications, Oxford, UK (2001).
100. Krebs CJ. Ecological Methodology. 2nd Edition. Harlow. Benjamin/Cummings, CA, USA (1999).
101. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control. Clin. Trials 2, 93-113 (1981).